AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02549612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moniri Otovent
Description: Please see arm description.
Study NCT03945812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma Arm
Description: Platelet Rich Plasma Arm
Study NCT03945812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline 9%
Study NCT00638820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell or Umbilical Cord Blood Transplantation
Description: Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
Study NCT00638820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath, Busulfan, Clofarabine
Description: * 12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~* 11 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 10 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 9 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours~* 8 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours~* 7 Rest~* 6 Clofarabine 40 mg/m2 intravenously over 2 hours~* 5 Clofarabine 40 mg/m2 intravenously over 2 hours~* 4 Clofarabine 40 mg/m2 intravenously over 2 hours~* 3 Clofarabine 40 mg/m2 intravenously over 2 hours~* 2 Clofarabine 40 mg/m2 intravenously over 2 hours
Study NCT00638820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation
Description: Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
Study NCT02848781 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator (ICD)
Description: An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
Study NCT02848781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD)
Description: An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
Study NCT02848781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
Study NCT02848781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
Study NCT02132065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
Study NCT02279082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-02
Description: Active Experimental Drug
Study NCT05196386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Admission conciliation interview
Description: Previous treatment conciliation at hospital admission
Study NCT05196386 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Admission conciliation interview
Description: Previous treatment conciliation at hospital admission
Study NCT05196386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge conciliation interview
Description: Allocated treatment during hospital stay
Study NCT05196386 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Discharge conciliation interview
Description: Allocated treatment during hospital stay
Study NCT05196386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted pharmaceutical interview
Description: Specific information about treatment delivered by pharmacist
Study NCT04487886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.
Study NCT04487886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo to match duvelisib will be taken orally twice per day for 14 days.
Study NCT03892876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Auditory High Frequency Tetanizing Stimulation
Description: 50 ms tone pips presented at high frequency for 120 seconds
Study NCT03892876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: auditory tone pips with interstimulus interval (ISI) 1 sec
Study NCT02081352 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DermaPure™
Description: A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)
Study NCT02081352 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Study NCT01280305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Description: raloxifene 60 mg bid
Study NCT01280305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo bid
Study NCT03358407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2983559
Description: GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
Study NCT01705795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab (a-IL-5 antibody)
Description: 750mg mepolizumab four times over four months
Study NCT01705795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nacl four times over four months
Study NCT01854476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pad-gauze with tranexamic acid (Hemostopan™)
Description: The use of pad-gauze containing tranexamic acid (Hemostopan™)
Study NCT03358407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsules matching GSK2983559 will be available for subjects.
Study NCT01511367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutiform
Description: 50/5ug (fluticasone/formoterol) 2 puffs twice daily
Study NCT01511367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: 50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
Study NCT01511367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flixotide
Description: 50ug 2 puffs twice daily
Study NCT01382875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary management program
Description: conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
Study NCT03936010 — intervention group
Intervention type: DRUG
Intervention: Canagliflozin
Description: Canagliflozin dispensing claim is exposure
Study NCT03936010 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: DPP4 inhibitor dispensing claim is reference
Study NCT02142790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel liposome injection
Study NCT01678391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Common bile duct stone removal without fluoroscopy.
Description: ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
Study NCT01683565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCPUFA oil supplement
Description: 2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)
Study NCT01683565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Canola Oil Placebo
Description: 2.5mL per day for 90 days
Study NCT02515331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHW090
Description: Capsule - oral dose
Study NCT02515331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule - oral dose
Study NCT03565900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose.
Study NCT03565900 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
Study NCT03565900 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study NCT03565900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study NCT00687739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: progressive resistance exercise training
Description: 45 minute exercise sessions 4 times per week for 5 months
Study NCT00687739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive resistance exercise training
Description: 45 minute exercise sessions 4 times per week for 5 months
Study NCT00945256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: 45 minuties of treadmill walking was completed at 40% VO2 peak
Study NCT00945256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
Study NCT00945256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid Drink
Description: 7.5 gram Amino Acid drink
Study NCT01828229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: female inactivity and hypercaloric diet
Description: female inactivity and hypercaloric diet for 2 weeks
Study NCT01828229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inactivity
Description: inactivity for 2 weeks
Study NCT01828229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inactivity and hypercaloric diet
Description: inactivity and hypercaloric diet for 2 weeks
Study NCT01828229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normal activity and hypercaloric diet
Description: normal activity and hypercaloric diet for 2 weeks
Study NCT01828229 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: inactivity and iso-caloric diet
Description: inactivity and iso-caloric diet for 2 weeks
Study NCT03744767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 MG
Description: oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
Study NCT00186173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After school sports program
Description: After school team sports intervention designed specifically for overweight and obese children
Study NCT00186173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: After school health education
Description: After school health and nutrition education program
Study NCT02926768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-101
Description: Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily
Study NCT02513901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
Study NCT04624295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early aspirin Therapy
Description: Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
Study NCT00820612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: 100 mg PR once at the time of ERCP
Study NCT00820612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suppositories
Description: 2 placebo suppositories at the time of ERCP
Study NCT00436748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Administered by subcutaneous or intravenous injection
Study NCT00436748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
Study NCT04624295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-Early aspirin Therapy
Description: Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
Study NCT02600559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201 (ciprofloxacin)
Study NCT04156009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activated Lavender Elequil aromatabs® (#372)
Description: Activated Lavender aromatherapy tablets wrapped in tape
Study NCT02033733 — intervention group
Intervention type: DRUG
Intervention: Cisatracurium infusion
Description: This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group).
Study NCT04156009 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Unactivated Lavender Elequil aromatabs® (#372)
Description: Unactivated Lavender aromatherapy tablets wrapped in tape
Study NCT02682966 — intervention group
Intervention type: RADIATION
Intervention: Coronary Computed Tomography Angiography
Description: Coronary Computed Tomography Angiography will be performed in all participants
Study NCT03156426 — intervention group
Intervention type: OTHER
Intervention: Event of interest: Acute kidney injury
Description: AKI as defined by AKIN staging
Study NCT03011801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy
Description: reducing conflict in relationships, increasing social support in relationships, improving communication, reducing depressive symptoms
Study NCT03011801 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced usual care
Description: Treatment as Usual, including eclectic and supportive therapy, as well as psychiatric medication
Study NCT03227458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.
Study NCT03227458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo daily for 36 weeks.
Study NCT03227458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: bone-loading exercise on 3 days per week for 38 weeks
Study NCT02033733 — intervention group
Intervention type: DRUG
Intervention: Cisatracurium prn bolus
Description: Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
Study NCT02489747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: WBE
Description: wheat bran extract (3 g/day)
Study NCT02489747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01610791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, total of 6 infusions
Study NCT03922568 — intervention group
Intervention type: OTHER
Intervention: Density Gradient Centrifugation
Description: semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
Study NCT03922568 — intervention group
Intervention type: DEVICE
Intervention: Physiological ICSI
Description: Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
Study NCT03922568 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Activated Cell Sorting
Description: Semen processing is done by double layer density gradient method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
Study NCT01971827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI-KIDS
Description: MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
Study NCT00482391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00482391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00482391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00482391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Study NCT00482391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00482391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00993785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Costar Coronary Stent Delivery System
Study NCT02148328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent virosomal influenza vaccine
Description: Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
Study NCT02148328 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial vaccine 1
Description: Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
Study NCT02148328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent virosomal influenza vaccine
Description: Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
Study NCT02951182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Study NCT02951182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ
Study NCT02148328 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial vaccine 2
Description: Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
Study NCT01069055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
Study NCT01069055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lornoxicam
Description: Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
Study NCT01069055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol
Description: Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
Study NCT01664143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple doses of placebo
Study NCT01664143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5508887
Description: Multiple doses of RO5508887